ImetelChat

BP:
Your exchanges with MG on the workings of clinical trials these past few weeks have been invaluable. I have even come to tolerate AI for a spell. Thank you all.

BP:
I'm confused. Are you suggesting that the newer Rux therapies have corrupted IMpact?

BP:
Individual shareholders are minions, peons, vermin, lab rats, and it was ever thus.

What to ask at the shareholders’ meeting?
Poring through biopearl’s observations, I have come to believe Geron is on the verge of acquiring Breakthrough Therapy Designation, a long dreamed of result for this company. We deserve this accolade whereby Rytelo has the means to extend life in perhaps 85 ...

How do you propose we do that?

If management was obliged to sign a non-disclosure agreement, that might explain their behavior. They seem to feel the need to keep their strategies secret, and perhaps they’re right to play this hand close to the chest. I can only speculate. December 1st we will find out if we filed any late ...

Biopearl,
We all know that lawyers are the devil’s spawn, but they had nothing to do with designing this Impact trial. What are we to do with its remains? I agree with Hunt: Geron has a built in disadvantage. Our possibly stellar response will be seriously diluted if placebo patients cross over ...

Biopearl,
I wouldn’t blame the lawyers for this fiasco, I blame the physicians. Here we’ve been holding our breath for years for the outcome of these trials, when they are hopelessly defective. I hope this quandary is at the center of our presentation at ASH.

This is great news, biopearl.
The rights to the patent are transferred to Geron, giving credit to Sergei as inventor. Looks like we're still best buds.

What a pleasure to read details of the Mayo trial from 2013, short, sweet, and remarkable. Yet it was swept away as I recall because the presiding standard of care for ET was ‘sufficient,’ so there was no need to proceed with a Phase 3 trial. We moved on.
Can we expect that the Phase 3 Impact trial ...

Didn't Dr Tefferi attempt to patent his method of treating patients, and that's why he and Geron parted ways?
seedylemon

BP:
Now that we have FDA approval for LR MDS, we have our foot in the door. Apparently oncologists, if they are so inclined, can explore the use of imetelstat along other avenues. This week Geron began a search for a director who would expand our foot print into the field of lymphatic cancers. The ...

Doesn't the form show that he exercised options to buy 3 million shares for the very first time?

Chief Scarlett bought 3 million shares on Valentine's Day. Has he ever done that before? I am encouraged.